Decreased maternal serum cortistatin levels in pregnancies with gestational diabetes mellitus

Simple item page
dc.contributor.authorAkbas M.
dc.contributor.authorKoltan S.O.
dc.contributor.authorKoyuncu F.M.
dc.contributor.authorArtunc Ulkumen B.
dc.contributor.authorTaneli F.
dc.contributor.authorOzdemir H.
dc.date.accessioned2025-04-10T11:06:31Z
dc.date.available2025-04-10T11:06:31Z
dc.date.issued2020
dc.description.abstractObjective: To investigate serum cortistatin levels in women with gestational diabetes mellitus (GDM) and women with uncomplicated pregnancies. Material and methods: This case-control study consisted of 40 pregnancies with GDM and 41 healthy singleton pregnancies matched for maternal and gestational age. The maternal serum levels of cortistatin were measured with enzyme-linked immunosorbent assay and compared between groups. Results: Cortistatin levels were significantly lower in GDM group (48.85 ± 20.18 versus 65.84 ± 33.98 ng/ml, p =.008). There was a statistically significant difference in cortistatin levels between different treatment modalities and control group (χ2(2) = 8.828, p =.012). Pairwise comparisons showed that diet group had significantly lower CST levels than control group (p =.012). Serum cortistatin levels were negatively correlated with serum insulin and glucose levels and HOMA-IR (r = −0.358, p =.001; r = −0.303, p =.006; r = −0.444, p <.001, respectively). Conclusion: Cortistatin levels were significantly lower in GDM pregnancies and related to serum insulin and glucose levels and HOMA-IR in pregnancy. This may help to better clarify the mechanism of GDM pathogenesis. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
dc.identifier.DOI-ID10.1080/14767058.2019.1627321
dc.identifier.urihttp://hdl.handle.net/20.500.14701/46762
dc.publisherTaylor and Francis Ltd
dc.titleDecreased maternal serum cortistatin levels in pregnancies with gestational diabetes mellitus
dc.typeArticle

Files

Collections

Scopus Koleksiyonu